Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Pharmacotherapy of cardiovascular comorbidities in osteoporotic postmenopausal women

Cover Page

Abstract


Aim: to assess tolerability and efficacy of cardiovascular comorbidities pharmacotherapy in osteoporotic postmenopausal women.

Methods: cross-sectional study included 112 osteoporotic postmenopausal women aged from 49 to 85.

Results: 95 persons (84.8%) had indications for angiotensine-convertising enzyme inhibitors (ACEI) prescription. Cough was associated with significantly higher odds of coronary heart disease, congestive heart failure and a trend to multiple bone fractures. Valsartan was initiated in 32 coughing patients. Target blood pressure level was reached in 15 women. In 15 cases blood pressure levels decreased by 30% of baseline level.

Conclusion: efficacy of cardiovascular diseases in osteoporotic postmenopausal women treatment needs to be assessed in specially designed clinical trials.


Nadezhda V. Izmozherova

Ural State Medical University

Email: fake@endojournals.ru

Russian Federation, Yekaterinburg

MD, PhD, professor

Artem A. Popov

Ural State Medical University

Author for correspondence.
Email: art_popov@mail.ru

Russian Federation, Yekaterinburg

MD, PhD, professor

  1. Лесняк О.М., Алексеева Л.И., Баранова И.А., и др.; Российская ассоциация по остеопорозу. Клинические рекомендации по профилактике и ведению больных с остеопорозом. Издание 2-ое, дополненное. – Ярославль: Литера, 2016. [Lesnyak OM, Alekseeva LI, Baranova IA et al.; Rossiyskaya assotsiatsiya po osteoporozu. Klinicheskie rekomendatsii po profilaktike i vedeniyu bol'nykh s osteoporozom. Second edition. Yaroslavl: Litera; 2016 (In Russ.)].
  2. Скрипникова И.А., Оганов Р.Г. Остеопороз и сердечно-сосудистые заболевания (ССЗ) обусловленные атеросклерозом (АС) у женщин постменопаузального периода: общность поведенческих и социальных факторов риска // Остеопороз и остеопатии. - 2009. - Т. 12. - №2. - C. 5-9. [Skripnikova IA, Oganov RG. Osteoporoz i serdechno-sosudistye zabolevaniya (SSZ) obuslovlennye aterosklerozom (AS) u zhenshchin postmenopauzal'nogo perioda:obshchnost' povedencheskikh i sotsial'nykh faktorov riska. Osteoporosis and osteopathy. 2009;12(2):5-9. (In Russ.)] doi: 10.14341/osteo200925-9.
  3. den Uyl D, Nurmohamed MT, van Tuyl LHD, et al. (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis research & therapy 2011;13(1):R5. doi: 10.1186/ar3224.
  4. Jorgensen L. Low Bone Mineral Density Is Related to Echogenic Carotid Artery Plaques: A Population-based Study. American journal of epidemiology. 2004;160(6):549-556. doi: 10.1093/aje/kwh252.
  5. Майчук, Е.Ю., Митрохина, Т.В., Воеводина, И.В. и др. Сопоставление уровней маркеров атеросклероза и факторов риска сердечно-сосудистых заболеваний с минеральной плотностью кости у женщин применопаузального периода и раннего течения естественной постменопаузы. // Проблемы женского здоровья. – 2016. – Т. 11. – №. 3. – С. 35-44. [Maichuk EY, Mitrokhina TV, Voevodina IV. Comparison of the level of markers of atherosclerosis and risk factors of cardiovascular disease with mineral density of bone in women of perimenopausal period and the early flow of natural menopause. Problems of women health. 2016;11(3):35-44. (In Russ)].
  6. Magnus JH, Broussard DL. Relationship between bone mineral density and myocardial infarction in US adults. Osteoporos Int. 2005;16(12):2053-2062. doi: 10.1007/s00198-005-1999-9.
  7. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012;33(13):1635-1701. doi: 10.1093/eurheartj/ehs092.
  8. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). // Журнал сердечная недостаточность. – 2013. – Т. 14. – №. 7. – С. 379-472. [Mareev VYu, Ageev FT, Arutyunov GP et al. SEHF, RSC AND RSMSIM National guidelines on CHF diagnostics and treatment (fourth revision). Heart Failure Journal. 2013;14(7):379-472 (In Russ.)] doi: 10.18087/rhfj.2013.7.1860.
  9. Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск) // Сахарный диабет. – 2015. – Т. 18. – №1S. – C. 1-112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (7-th edition). Diabetes mellitus. 2015;18(1S):1-112. (in Russ.)] doi: 10.14341/DM20151S.
  10. Dicpinigaitis PV. Angiotensin-Converting Enzyme Inhibitor-Induced Cough. Chest. 2006;129(1):169S-173S. doi: 10.1378/chest.129.1_suppl.169S.
  11. Silverman SL, Delmas PD, Kulkarni PM, et al. Comparison of Fracture, Cardiovascular Event, and Breast Cancer Rates at 3 Years in Postmenopausal Women with Osteoporosis. J Am Geriatr Soc. 2004;52(9):1543-1548. doi: 10.1111/j.1532-5415.2004.52420.x.
  12. Rutledge T, Matthews K, Lui L-Y, et al. Social Networks and Marital Status Predict Mortality in Older Women. Psychosom Med. 2003;65(4):688-694. doi: 10.1097/01.psy.0000041470.25130.6c.
  13. Butt DA, Mamdani M, Gomes T, et al. Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly. J Bone Miner Res. 2014;29(11):2483-2488. doi: 10.1002/jbmr.2271.
  14. Aoki M, Kawahata H, Sotobayashi D, et al. Effect of angiotensin II receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome. Geriatrics & Gerontology International. 2015;15(8):1064-1072. doi: 10.1111/ggi.12406.
  15. White HD. Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction: Results From the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation. 2005;112(22):3391-3399. doi: 10.1161/circulationaha.105.551143.
  16. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. N Engl J Med. 1987;316(23):1429-1435. doi: 10.1056/nejm198706043162301.
  17. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. J Am Coll Cardiol. 2003;41(9):1529-1538. doi: 10.1016/s0735-1097(03)00262-6.
  18. Morice AH. Cough * 1: Chronic cough in adults. Thorax. 2003;58(10):901-907. doi: 10.1136/thorax.58.10.901.
  19. Скрипникова И.А., Собченко К.Е., Абирова Э.С., и др. Изучение плейотропных эффектов в-адреноблокаторов и ингибиторов апф на костную ткань // Остеопороз и остеопатии. - 2014. - Т. 17. - №1. - C. 3-7. [Skripnikova IA, Sobchenko KE, Abirova ES, et al. Izuchenie pleyotropnykh effektov v-adrenoblokatorov i ingibitorov APF na kostnuyu tkan'. Osteoporosis and osteopathy. 2014;17(1):3-7. (In Russ)] doi: 10.14341/osteo201413-7.
  20. Lynn H, Kwok T, Wong SYS, et al. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone. 2006;38(4):584-588. doi: 10.1016/j.bone.2005.09.011.

Views

Abstract - 1252

PDF (Russian) - 348

Cited-By


PlumX


Copyright (c) 2017 Izmozherova N.V., Popov A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.